IPQ Inside the global regulatory dialogue

KASA and PQ/CMC Initiatives Gain Momentum in FDA’s Effort to Strengthen Quality Review Process

Aug 11th, 2019

Please Log in to print the full article

FDA’s Rosencrance Outlines KASA’s Objectives Office of Lifecycle Drug Products Director Susan Rosencrance began the KASA session by providing a high-level overview of the shortcomings in the current application review process and how KASA will...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2020 IPQ Publications